Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

Intellia Therapeutics has said it will reduce its ... its resources behind two priority drug candidates. The specialist in CRISPR-based gene editing – co-founded by Nobel Prize winner Jennifer ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Intellia has reported results from a phase ... Earlier this year, Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel) for sickle cell disease and beta thalassaemia became ...

All You Need to Know About Intellia Therapeutics Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered ...

Intellia Therapeutics' most advanced product candidates, NTL-2002 and Next-z, are aimed as in vivo gene therapies, using Crispr/Cas9 encapsulated in their proprietary LNP, which after being ...

Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...

CRISPR biotech Intellia Therapeutics has announced plans to reduce its workforce by 27% and halt early-stage R&D programmes as it concentrates resources on two late-stage drug candidates.

It has been many moons since I last held a position in Intellia Therapeutics ... their staff and halt the development of one of their CRISPR candidates, NTLA-3001 for alpha-1 antitrypsin ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats ...